Cargando…

Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy

OBJECTIVE: Myotonic dystrophy type 1 (DM1) is caused by the expansion of a CTG repeat in the 3′ untranslated region of DMPK. The transcripts containing an expanded CUG repeat (CUG (exp)) result in a toxic gain‐of‐function by forming ribonuclear foci that sequester the alternative splicing factor mus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamori, Masayuki, Taylor, Katarzyna, Mochizuki, Hideki, Sobczak, Krzysztof, Takahashi, Masanori P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704483/ https://www.ncbi.nlm.nih.gov/pubmed/26783549 http://dx.doi.org/10.1002/acn3.271

Ejemplares similares

Cellular Senescence and Aging in Myotonic Dystrophy
por: Hasuike, Yuhei, et al.
Publicado: (2022)

Expanded CUG Repeat RNA Induces Premature Senescence in Myotonic Dystrophy Model Cells
por: Hasuike, Yuhei, et al.
Publicado: (2022)

Global Increase in Circular RNA Levels in Myotonic Dystrophy
por: Czubak, Karol, et al.
Publicado: (2019)

Pharmacotherapy alleviates pathological changes in human direct reprogrammed neuronal cell model of myotonic dystrophy type 1
por: Eltahir, Mougina K., et al.
Publicado: (2022)

Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1
por: Nakamori, Masayuki, et al.
Publicado: (2022)

Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1
por: Wojciechowska, Marzena, et al.
Publicado: (2014)

Sustainable recovery of MBNL activity in autoregulatory feedback loop in myotonic dystrophy
por: Rogalska, Zuzanna, et al.
Publicado: (2022)

Targeting nuclear RNA for in vivo correction of myotonic dystrophy
por: Wheeler, Thurman M., et al.
Publicado: (2012)

Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy
por: Wojciechowska, Marzena, et al.
Publicado: (2018)

Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy
por: Thomas, James D., et al.
Publicado: (2017)

Autistic traits in myotonic dystrophy type 1 due to MBNL inhibition and RNA mis-splicing
por: Sznajder, Lukasz, et al.
Publicado: (2023)

Straightjacket/α2δ3 deregulation is associated with cardiac conduction defects in myotonic dystrophy type 1
por: Auxerre-Plantié, Emilie, et al.
Publicado: (2019)

Muscleblind-Like 1 Knockout Mice Reveal Novel Splicing Defects in the Myotonic Dystrophy Brain
por: Suenaga, Koichi, et al.
Publicado: (2012)

Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability
por: Ueki, Junko, et al.
Publicado: (2017)

Quercetin selectively reduces expanded repeat RNA levels in models of myotonic dystrophy
por: Mishra, Subodh K., et al.
Publicado: (2023)

Deregulations of miR‐1 and its target Multiplexin promote dilated cardiomyopathy associated with myotonic dystrophy type 1
por: Souidi, Anissa, et al.
Publicado: (2023)

Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules
por: Reddy, Kaalak, et al.
Publicado: (2019)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy
por: Wojtkowiak-Szlachcic, Agnieszka, et al.
Publicado: (2015)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy
por: Tanner, Matthew K, et al.
Publicado: (2021)

Detection of Slipped-DNAs at the Trinucleotide Repeats of the Myotonic Dystrophy Type I Disease Locus in Patient Tissues
por: Axford, Michelle M., et al.
Publicado: (2013)

Cardiac Conduction Disorders as Markers of Cardiac Events in Myotonic Dystrophy Type 1
por: Itoh, Hideki, et al.
Publicado: (2020)

From dynamic combinatorial ‘hit’ to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy
por: Ofori, Leslie O., et al.
Publicado: (2012)

AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1
por: Stepniak-Konieczna, Ewa, et al.
Publicado: (2020)

Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy
por: Freyermuth, Fernande, et al.
Publicado: (2016)

Modifications to toxic CUG RNAs induce structural stability, rescue mis-splicing in a myotonic dystrophy cell model and reduce toxicity in a myotonic dystrophy zebrafish model
por: deLorimier, Elaine, et al.
Publicado: (2014)

Desflurane anaesthesia in myotonic dystrophy
por: Gandhi, Ranju, et al.
Publicado: (2011)

Myotonic Dystrophy: An Anaesthetic Dilemma
por: Gupta, N, et al.
Publicado: (2009)

Cardiac involvement in myotonic dystrophy
por: Khalighi, Koroush, et al.
Publicado: (2015)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Cutaneous findings in myotonic dystrophy
por: Kong, Ha Eun, et al.
Publicado: (2022)

Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes
por: Dincã, Diana M., et al.
Publicado: (2022)

Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy
por: Mootha, V. Vinod, et al.
Publicado: (2017)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Respiratory failure in myotonic dystrophy 1
Publicado: (2013)

Multidimensional aspects of pain in myotonic dystrophies
por: Peric, Marina, et al.
Publicado: (2015)

Myotonic Dystrophy—A Progeroid Disease?
por: Meinke, Peter, et al.
Publicado: (2018)

Hyperostosis Frontalis Interna in Myotonic Dystrophy
por: Suzuki, Keisuke, et al.
Publicado: (2017)

Core Clinical Phenotypes in Myotonic Dystrophies
por: Wenninger, Stephan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6kja3bh1m813bov6m2n0v06kbn